Overview

To Assess Safety, Tolerability and PK of NEX-20A, a Subcutaneous Prolonged-release Injection to Healthy Subjects

Status:
Not yet recruiting

Trial end date:
2023-09-30

Target enrollment:

Participant gender:

Summary

This is a single-centre, single ascending dose (SAD) pilot study designed to evaluate the safety, tolerability, including local tolerability, and pharmacokinetics (PK) of NEX-20A (lenalidomide) after the administration of a single subcutaneous prolonged-release injection to healthy male volunteers

Phase:

Early Phase 1

Details

Lead Sponsor:

Nanexa AB

Collaborator:

CTC Clinical Trial Consultants AB